Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment
ESMO Virtual Congress 2020
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may have a place in treating patients with metastatic renal cell carcinoma (Abstract 696O_PR).
The ASCO Post Staff
Andreas Schneeweiss, MD, of the Heidelberg University Hospital and German Cancer Research Center, discusses phase III survival data from the GeparOcto trial, which compared the neoadjuvant chemotherapy intense dose-dense EPC (epirubicin, paclitaxel, and cyclophosphamide) with weekly paclitaxel and liposomal doxorubicin (with or without carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (Abstract 160O).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses long-term STAMPEDE trial results that showed patients with metastatic, hormone-naive prostate cancer benefited from abiraterone acetate plus prednisolone in terms of overall and failure-free survival, as well as skeletal-related events (Abstract 611O).
The ASCO Post Staff
Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III melanoma, as well as a decrease in the incidence of distant and locoregional recurrence (Abstract LBA46).
The ASCO Post Staff
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected stage III/IV melanoma (Abstract 1076O).
The ASCO Post Staff
Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities and a slight decline in quality of life, it did not lead to fewer emergency department visits and hospitalizations (Abstract LBA87).
